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Abstract
BACKGROUND—The role of adjuvant chemoradiation therapy (CRT) in pancreatic cancer
remains controversial. The primary aim of this study was to determine if CRT improved survival
in patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients.
STUDY DESIGN—Patients undergoing resection for pancreatic adenocarcinoma from seven
academic medical institutions were included. Exclusion criteria included patients with T4 or M1
disease, R2 resection margin, preoperative therapy, chemotherapy alone, or if adjuvant therapy
status was unknown.
RESULTS—There were 747 patients included in the initial evaluation. Primary analysis was
performed between patients that had surgery alone (n = 374) and those receiving adjuvant CRT (n
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= 299). Median followup time was 12.2 months and 14.5 months for survivors. Median overall
survival for patients receiving adjuvant CRT was significantly longer than for those undergoing
operation alone (20.0 months versus 14.5 months, p = 0.001). On subset and multivariate analysis,
adjuvant CRT demonstrated a significant survival advantage only among patients who had lymph
node (LN)-positive disease (hazard ratio 0.477, 95% CI 0.357 to 0.638) and not for LN-negative
patients (hazard ratio 0.810, 95% CI 0.556 to 1.181). Disease-free survival in patients with LN-
negative disease who received adjuvant CRT was significantly worse than in patients who had
surgery alone (14.5 months versus 18.6 months, p = 0.034).
CONCLUSIONS—This large multiinstitutional study emphasizes the importance of analyzing
subsets of patients with pancreas adenocarcinoma who have LN metastasis. Benefit of adjuvant
CRT is seen only in patients with LN-positive disease, regardless of resection margin status. CRT
in patients with LN-negative disease may contribute to reduced disease-free survival.
There will be an estimated 37,170 new cases of pancreas cancer, with nearly as many deaths
in the US in 2008. Although this accounts for only 2% of all newly diagnosed malignancies,
pancreas cancer is the fourth leading cause of cancer death.1 Most patients with pancreatic
cancer present with advanced disease at the time of diagnosis, and only 10% to 15% of
patients are candidates for potentially curative resection.2–4 The rationale for adjuvant
therapy is based on the high incidence of tumor recurrence both locally and at distant sites,
presumably because of the presence of micrometastatic disease after surgical resection.
The Gastrointestinal Study Group (GITSG) first studied the role of adjuvant chemoradiation
therapy (CRT) for pancreas cancer.5 The study was closed early because of the slow accrual
of only 43 patients over 8 years, and the interim analysis showed a statistically significant
benefit for the adjuvant therapy arm. Based on this, the GITSG trial established CRT as a
viable option after pancreatic cancer resection within the US, but less so elsewhere. Since
the GITSG trial, other trials have suggested that adjuvant chemotherapy alone may be
beneficial in the adjuvant setting for pancreas cancer,6–8 but no randomized trial has been
able to convincingly support the role of radiation therapy, and this issue sparks considerable
debate throughout the world.
Multiple reasons exist as to why these trials have failed to obtain a greater understanding of
the role of CRT in pancreas cancer. Limitations of these randomized trials include small
numbers of patients in the treatment arms,5 poor compliance with the treatment regimens,5,7
variable pathologic criteria for study entry including combining patients with pancreatic
adenocarcinoma with other periampullary malignancies,6,7 and flawed randomization
schemes.7 In addition, patients with positive (R1) and negative (R0) margins of resection
and positive and negative lymph nodes (LN) are assessed as a uniform group. So patient
populations vary considerably among these trials and comparative analysis becomes
impossible.
Recent large single-institution studies9,10 and data from the Surveillance, Epidemiology, and
End Results (SEER) database,11 however, have suggested a significant benefit for adjuvant
CRT after surgery for pancreas cancer. These studies, although analyzing large numbers of
patients, are limited by institutional biases and by analysis of patients treated over many
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years, during which time our diagnostic capabilities, operative morbidity and mortality, and
techniques for delivery of radiation and chemotherapy have improved substantially.4,12
The primary aim of this study was to determine if adjuvant CRT improves survival in
patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients. This
analysis dilutes the biases of individual institutions and allows for independent analysis of
subsets of patients. We sought to determine if adjuvant CRT benefits only a subset of
patients who are LN positive or those with R1 resection margins.
METHODS
This is an institutional review board-approved, multiinstitutional review of prospectively
maintained databases from seven academic medical centers of the Central Pancreas
Consortium. Patients with pancreas adenocarcinoma who underwent surgical resection from
January 2000 to December 2006 from five centers and from January 1996 to December
2006 from two centers were analyzed. Patients were excluded if they were found to have T4
or M1 disease or R2 resection margins at the time of operation, if they received preoperative
therapy, or if their adjuvant therapy status was unknown. A total of 747 patients were
included in the initial evaluation. Of these, 374 patients had surgery alone, 299 patients
received adjuvant CRT, and 74 patients received adjuvant chemotherapy alone. Adjuvant
radiation therapy alone was identified as a treatment regimen in six patients; these patients
were included in the CRT group. Primary analysis for this study was performed between
patients who had surgery alone (n = 374) and those receiving adjuvant CRT (n = 299).
Patients receiving chemotherapy alone were excluded from the primary analysis.
All pathology and operative reports were reviewed to determine the extent of resection.
Resection margins were considered positive (R1) if the carcinoma was close (within 1 mm)
or present at the final pancreatic neck, uncinate process, bile duct, or duodenal or
retroperitoneal soft tissue margin, consistent with American Joint Committee on Cancer
(AJCC) definitions.13 Perineural and lymphovascular invasion were not recorded routinely,
so were not included in the final analysis. Tumor grade was consistently reported and
included. Because of the update to the American Joint Committee on Cancer staging manual
in 2002, staging was inconsistent throughout the study period, so was not evaluated.
All patients underwent surgical resection at the centers involved in this study. Being tertiary
referral centers, many patients received their adjuvant therapy at outside hospitals, so
specific adjuvant therapy regimens were not able to be determined for all patients, but the
majority of patients received 5-fluorouracil (5-FU)-based chemotherapy with conformal
radiation therapy. Only patients who had verification of their therapy were included the
study.
Statistical analysis
The Wilcoxon test and the Fisher’s exact test were used as appropriate to test for differences
in patient characteristics between the two treatment groups. Overall survival (OS) was
defined as the time from operation to death for any reason. For OS, patients alive at last
contact were censored at their last followup time. Disease-free survival (DFS) was defined
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as the time of operation to time of first recurrence or death for any reason. Patients alive and
recurrence-free were censored at last followup. Survival distributions were estimated using
the method of Kaplan and Meier. The proportions of individuals surviving up to 2 and 5
years were estimated, and standard errors for 95% confidence intervals were estimated using
Greenwood’s formula. Survival comparisons by treatment arm were performed using the log
rank test. The impact of multiple prognostic variables on OS and DFS were assessed using
the Cox (proportional hazards) regression model stratifying by institution. Comparisons with
p values < 0.05 were considered statistically significant.
RESULTS
Median followup time for all patients was 12.2 months and 14.5 months for survivors.
Demographic data for patients are shown in Table 1, including the number of patients in
each treatment arm by institution. The mean age for the entire cohort of patients was 65.0
±11.3 years. Patients receiving adjuvant CRT were younger than those undergoing surgery
alone (CRT, 63.0 ± 10.3 years versus surgery, 67.0 ± 11.7 years, p < 0.001). There was an
equal distribution of men and women. Tumors were larger in patients who received CRT
(3.03 ± 1.36 cm versus 3.28 ± 1.45 cm, p = 0.048). Other tumor characteristics such as grade
and location were similar between the two groups. Patients in the CRT arm had a greater
incidence of LN-positive disease (CRT, 65% versus surgery, 56%, p = 0.027) and R1
resections (CRT, 33% versus surgery, 20%, p = 0.00014). The complication rates were
similar between both groups. Length of stay was significantly longer in patients who
underwent surgery alone compared with those who received adjuvant CRT (CRT, 9 ± 6.0
days versus surgery, 10 ± 9.4 days, p < 0.001).
Overall survival
Table 2 shows the median OS for the entire group of patients treated with adjuvant CRT or
surgery alone and patients stratified by resection margin status (R0 versus R1) and by LN
status (LN positive versus LN negative). When comparing the entire cohort of patients by
treatment arm, OS was significantly improved for patients receiving CRT after surgery
compared with those undergoing surgery alone (20 months versus 14.5 months, p = 0.001).
Comparison of the subset of patients with R0 versus R1 resection margin and LN-positive or
LN-negative disease allows for analysis of which patients may truly benefit with adjuvant
CRT. Patients receiving adjuvant CRT showed significantly improved OS compared with
patients undergoing surgery alone, regardless of margin status. Patients who had either R0
(CRT, 23.4 months versus surgery, 15.9 months, p = 0.001) or R1 (CRT, 15.9 months versus
surgery, 8.9 months, p = 0.003) resection margins benefitted significantly with adjuvant
CRT. On the other hand, there were no statistically significant differences in OS between
patients with LN-negative disease who received adjuvant CRT and those who underwent
operation alone (22.9 months versus 24.2 months, respectively, p = 0.774); patients with
LN-positive disease showed a significant improvement in OS with adjuvant CRT compared
with those undergoing operation alone (19.4 months versus 10.4 months, p < 0.001).
Figure 1 shows the Kaplan-Meier survival curves for OS by treatment group. Two and 5-
year OS rates for patients receiving adjuvant CRT were 43.2% (95% CI, 37.2% to 50.2%)
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and 15.6% (95% CI, 10.0% to 24.4%), respectively, and for those undergoing surgery alone
were 33.5% (95% CI, 28.5% to 39.5%) and 19.0% (95% CI, 14.3% to 25.4%), respectively.
Figure 2 shows the overall survival curves for treatment groups stratified by resection
margin and LN status.
To assess the impact of resection margin and LN status together, we stratified patients into
the following sub-groups: R0, LN −; R0, LN + ; R1, LN−; and R1, LN+ (Table 2). This
analysis showed that LN-negative patients had no statistically significant benefit with
adjuvant CRT compared with those undergoing surgery alone, regardless of their resection
margin status. Lymph node-negative patients with either R0 (CRT, 29.6 months versus
surgery, 24.4 months, p = 0.441) or R1 (CRT, 15.6 months versus surgery, 15.4 months, p =
0.761) resection margins had similar OS in both treatment arms. On the other hand, LN-
positive patients showed a statistically significant benefit to receiving adjuvant CRT
compared with patients undergoing surgery alone with either R0 (CRT, 23.3 months versus
surgery, 10.8 months, p < 0.001) or R1 (CRT, 14.4 months versus surgery, 8.5 months, p =
0.002) resection margins.
To adjust for competing risk factors, we performed a multivariate analysis to assess whether
adjuvant CRT would remain a predictor of OS among LN-positive patients (Table 3). After
adjusting for age, gender, tumor location, size, grade, blood loss, transfusions, surgical
complications, and margin and node status as an interaction term, adjuvant CRT still
demonstrated a significant survival advantage compared with surgery alone among patients
who were LN positive (hazard ratio 0.477, 95% CI 0.357 to 0.638). There was insufficient
evidence to suggest that adjuvant CRT provided a survival advantage compared with
surgery alone among patients who were LN negative (hazard ratio 0.810, 95% CI 0.556 to
1.181). Other prognostic variables for OS included age, tumor size, advanced tumor grade,
increased blood loss, and R1 resection margin. Variables that did not affect OS included
tumor location, need for blood transfusion, vein resection, or complications within 30 days.
CRT, as seen in Table 2, significantly improved median OS in R0 patients by 7.5 months (p
= 0.001) and by 6.1 months in R1 patients (p = 0.003). This differential treatment
(interaction) effect with resection status of 1.4 months was tested in a separate regression
model and was not statistically significant (p = 0.980).
Disease-free survival
There was no significant difference seen in DFS between patients receiving adjuvant CRT
compared with those undergoing surgery alone when assessing the entire cohort of patients
(CRT, 12.8 months versus surgery, 10.8 months, p = 0.552), (Table 2). No differences in
DFS were seen with either R0 or R1 resection margin status by treatment arm (R0 CRT,
15.0 months versus surgery, 12.0 months, p = 0.429; R1 CRT, 10.1 months versus surgery,
6.5 months, p = 0.156). Interestingly, patients with LN-negative disease showed a
significantly worse DFS with adjuvant CRT compared with those undergoing surgery alone
(CRT, 14.5 months versus surgery, 18.6 months, p = 0.034). Patients with LN-positive
disease, however, showed a significantly improved DFS with adjuvant CRT (CRT, 12.3
months versus surgery, 7.2 months, p < 0.001).
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When assessing the impact of resection margin and LN status together, no differences in
DFS were seen in patients with LN-negative disease regardless of resection margin status
between the two treatment arms (Table 2). A trend toward worse DFS was seen in R0 and
LN-negative patients who received adjuvant CRT, but this did not achieve statistical
significance (CRT, 15.0 months versus surgery, 18.8 months, p = 0.072). Patients with LN-
positive disease who had an R0 resection showed a significant improvement in DFS with
adjuvant CRT (CRT, 15.4 months versus surgery, 9.0 months, p = 0.001), however, LN-
positive patients with R1 resections showed no difference in DFS between the two treatment
arms.
Kaplan-Meier survival curves for DFS by treatment group are shown in Figure 3. Two- and
5-year DFS rates for patients receiving adjuvant CRT were 25.2% (95% CI, 20.3% to
31.2%) and 10.3% (95% CI, 6.6% to 16.0%), respectively, and for those undergoing surgery
alone were 28.7% (95% CI, 24.1% to 34.3%) and 15.9% (95% CI, 11.7% to 21.6%),
respectively. Figure 4 shows the survival curves for treatment groups stratified by resection
margin and LN status.
Although there was no difference in DFS between patients receiving adjuvant CRT and
those undergoing surgery alone by log rank analysis, on multivariate analysis, after adjusting
for the variables listed in Table 4, and once again including an interaction term for lymph
node status, adjuvant CRT demonstrated a significant DFS advantage compared with
surgery alone among patients with positive LNs (hazard ratio 0.566, 95% CI 0.437 to 0.733).
There was no evidence to suggest adjuvant CRT provided a survival advantage compared
with surgery alone among patients who were LN negative (hazard ratio 1.170, 95% CI 0.832
to 1.645). Other prognostic variables for DFS were similar to those for OS and included age,
tumor size, advanced tumor grade, increased blood loss, and R1 resection margin. Variables
that did not affect DFS included tumor location, need for blood transfusion, vein resection,
or complications within 30 days. CRT, as can be seen in Table 2, improved median DFS by
3 months and 3.6 months for R0 (p = 0.429) and R1 patients (p = 0.156), respectively. This
differential treatment (interaction) effect with resection status of 0.6 months was tested in a
separate regression model and was not statistically significant (p = 0.600).
DISCUSSION
This large multiinstitutional study emphasizes the importance of analyzing subsets of
patients with pancreas adenocarcinoma who have LN metastasis and R1 resection margins.
This study suggests that patients receiving adjuvant CRT after surgical resection for
pancreatic adenocarcinoma achieve a significant OS benefit as compared with those
undergoing surgery alone. Subset analysis, however, revealed that the benefit of adjuvant
CRT is seen only in patients with LN-positive disease. Although patients with R0 or R1
resection margin showed a significant survival advantage with adjuvant CRT, this benefit
was not seen in patients with LN-negative disease and was seen only in LN-positive
patients. Similarly, for DFS, comparison of the entire group of patients revealed no
significant differences between patients receiving adjuvant CRT compared with those
undergoing surgery alone, but on subset analysis, a DFS advantage is seen only in patients
who have LN-positive disease and are receiving adjuvant CRT. In addition, the DFS in
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patients with LN-negative disease who received adjuvant CRT was actually significantly
worse than that in patients who had surgery alone.
Significant risk factors for recurrence after surgical resection for pancreas adenocarcinoma
include LN-positive disease and involved surgical margins.7,8,10 Outcomes for these patients
are significantly worse than those for patients with negative resection margins and LN-
negative disease. This finding was confirmed in our study. Clinical trials of adjuvant therapy
for pancreas cancer include 17% to 45% of patients who had an R1 resection and 45% to
80% of patients who have LN-positive disease.
Other pathologic criteria for study entry into clinical trials have also varied significantly.
The GITSG trial excluded LN-negative patients,5 the European Organization for Research
and Treatment of Cancer (EORTC) trial excluded patients with T3 or T4 tumors,6 and the
Charité Onkologie (CONKO)-001 trial excluded patients with postoperative CA19–9 or
carcinoembryonic antigen values greater than 2.5 times normal.8 The comparison of these
heterogeneous patient populations limits the evaluation of the role of adjuvant CRT in
pancreas cancer.
Results from the several published prospective and retrospective series evaluating the role of
adjuvant CRT are shown in Table 5. In the US, adjuvant CRT has been considered to be the
standard of care for more than 20 years by many clinicians. The rationale for this, however,
lies in the findings of the randomized GITSG study initially published in 1985.5 This trial
has been extensively criticized because of its small numbers, slow accrual, and use of
outdated split course radiation, and should, at this time, be considered only in historical
context.
The only other prospective study in the US that compared adjuvant CRT with surgical
resection alone for pancreas adenocarcinoma is a nonrandomized study from Johns
Hopkins.14 Patients were allowed to choose between standard therapy (similar to that used
in the GITSG study), intensified therapy (intensified radiation therapy to pancreatic bed and
liver with infusional 5-FU), or observation alone. The majority of patients chose standard
therapy and those that received adjuvant CRT showed an improvement in OS (CRT, 19.5
months versus surgery, 13.5 months, p = 0.003), with no difference seen between the two
CRT arms.
Data from European trials show a significant role for adjuvant systemic chemotherapy, but
fail to support a role for adjuvant CRT in pancreatic adenocarcinoma. The randomized
EORTC trial, consisting of both pancreatic cancers and periampullary tumors, also failed to
show a significant benefit with the use of CRT6 Even when analyzed for patients with
pancreatic adenocarcinoma alone, there was no benefit with the use of CRT.
In the European Study Group for Pancreatic Cancer (ESPAC-1) trial,7 patients in the 2×2
factorial design who received adjuvant CRT actually fared significantly worse than those
undergoing surgery alone. In contrast, however, those who received adjuvant systemic
chemotherapy had an increased OS compared with those who underwent surgery alone.
When both the 2×2 factorial arm and single-randomization arms were analyzed for
prognostic factors, the benefit of chemotherapy appeared most pronounced in patients with
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well-differentiated tumors, LN-positive disease, and margin-negative resection. The
detrimental effects of CRT, meanwhile, appeared to be most pronounced in patients with
moderately differentiated tumors, LN-positive disease, and negative resection margins.
Although this study has led to the virtual abandonment of adjuvant CRT in Europe, it has
been widely criticized in the US because of its complicated design, the lack of statistical
power in the 2×2 design, and the lack of radiation quality controls.
Recently, large retrospective series from Johns Hopkins and Mayo Clinic have suggested
that use of adjuvant CRT significantly improves OS compared with that in patients
undergoing surgery alone.9,10 In the study from Johns Hopkins, analysis of 616 patients
showed that the benefit of CRT was independent of several risk factors including tumor size,
grade, margin, and nodal status. Similar to results of this study, adjuvant CRT improved
survival for both margin-negative and margin-positive patients. In addition, LN-positive
patients appeared to have a significant benefit with adjuvant CRT, and LN-negative patients
did not. But by multivariate analysis, the interaction between nodal status and treatment was
not significant.
The recently reported Mayo Clinic experience of 472 patients who underwent R0 resection
also showed a significant survival benefit with the use of adjuvant CRT. This benefit was
present for both LN-positive and LN-negative disease. Although both these trials support the
findings of a benefit of adjuvant CRT, they were both nonrandomized single-institution
studies.
In this study, the presence of involved LNs was 60%, consistent with several other
randomized and nonrandomized series shown in Table 5. Also consistent with other
published series, the presence of positive LNs was associated with decreased survival. The
survival benefit of adjuvant CRT was seen only in LN-patients and not in LN-negative
patients and was consistent with the findings of John Hopkins study. In the Mayo Clinic
study, which evaluated only R0 resected patients, adjuvant CRT led to an improvement in
survival in both LN-negative and LN-positive patients. However the randomized ESPAC-1
trial adjuvant CRT was actually harmful in both LN-positive and LN-negative patients. The
decrease in DFS with adjuvant CRT for LN-negative patients seen in our study is an
intriguing finding and similar to the findings of the ESPAC-1 trial suggesting that these
patients may actually be harmed or certainly not helped with the use of adjuvant CRT.
The incidence of positive microscopic margins (R1) was 26% in this study. An R1 resection
margin was independently associated with worse OS and DFS, consistent with the findings
in several other studies.7,8,10 Although the use of adjuvant CRT improved OS in patients
with R0 and R1 margins in this study, this benefit was seen only in patients with LN-
positive disease. In the study from Johns Hopkins, the use of adjuvant CRT also showed a
survival advantage in patients with both positive and negative resection margins independent
of nodal status.
Despite the maturation of a number of randomized trials, little improvement in overall
survival or understanding of the appropriate adjuvant therapy in pancreas cancer have
materialized. This lack of progress is not simply the result of ineffective systemic therapies,
Merchant et al. Page 8






















but in part, the result of poor trial design and calls for a more disciplined approach to
designing future trials.15,16 Other critical factors necessary to improve the quality of data
obtained from future studies of adjuvant therapy include a systematic approach to the
selection of patients for surgery with the use of high quality pretreatment imaging and
defined radiographic criteria for resectability,17,18 and the use of a meticulous and
reproducible system for pathologic evaluation of resection margins.18 A recent consensus
conference sponsored by the Society of Surgical Oncology and the American Hepato-
Pancreatico-Biliary Association addressed these important issues and this article is
forthcoming. Future trials must also carefully define inclusion criteria and ensure better
quality control of treatment delivery, including standardized surgical technique, especially
for dissection along the superior mesenteric artery, where the majority of positive margin
resections occur.
This multiinstitutional study helps to overcome many of the limitations associated with
studies exploring the role of adjuvant CRT described earlier. It limits institutional biases and
evaluates large numbers of patients who had their surgical resection at experienced, high-
volume centers that treat pancreas cancer using a multidisciplinary approach. It is, however,
limited by its inherent retrospective approach. Many of the quality measures discussed
earlier could not be evaluated prospectively and could not be confirmed, particularly for the
adjuvant treatments, because many patients received their treatment at facilities other than
the primary institution where the surgical resection was performed.
Although no randomized trial has demonstrated the benefit of adjuvant CRT in resected
pancreas cancer, substantial data exist in a large number of patients to suggest that it may be
beneficial in certain high-risk subsets of patients (R1 resection margin and/or LN-positive
disease) and does not exclude the possibility of a therapeutic contribution of this treatment
strategy. Our results suggest that this benefit is limited to patients with LN-positive disease.
Data also exist from our study and that of the ESPAC-1 trial to suggest that in some patients,
particularly LN-negative patients, adjuvant CRT may actually be harmful. These data
emphasize the importance of determining which subsets of patients truly benefit from this
therapy and are not harmed by the morbidity of ineffective therapy.
Future studies will need to continue to assess the benefits of adjuvant chemotherapy and
CRT and should include stratification schemes to investigate the effects of adjuvant therapy
depending on resection margin status and LN status. Optimal staging, standardization and
quality control of surgical technique, pathologic evaluation and treatment delivery will also
need to be key components of trial design. The design of these trials should take into
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Kaplan-Meier survival curves for overall survival by treatment group. Two and 5-year
overall survivals for patients receiving adjuvant chemoradiation therapy (n = 299) were
43.2% (95% CI, 37.2% to 50.2%) and 15.6% (95% CI, 10.0% to 24.4%), respectively, and
for those undergoing surgery alone (n = 374) were 33.5% (95% CI, 28.5% to 39.5%) and
19.0% (95% CI, 14.3% to 25.4%), respectively. Overall survival with chemoradiation
therapy versus surgery, p = 0.001 by log rank analysis.
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Kaplan-Meier survival curves for overall survival for treatment groups stratified by resection
margin and lymph node (LN) status. (A) Patients with either R0 or R1 resection margin
benefitted significantly from adjuvant chemoradiation therapy (CRT) compared with those
undergoing surgery alone (R0 CRT [n = 200] versus R0 surgery [n = 298], p = 0.001; R1
CRT [n = 99] versus R1 surgery [n = 76], p = 0.003). (B) Only patients with LN-positive
disease benefitted from adjuvant CRT compared with patients undergoing surgery alone;
LN-negative patients showed no benefit with adjuvant CRT (LN+ CRT [n = 193] versus LN
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+ surgery [n = 208], p < 0.001; LN− CRT [n = 106] versus LN �� surgery [n = 164], p =
0.774).
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Kaplan-Meier survival curve for disease-free survival by treatment group. Two- and 5-year
disease-free survivals for patients receiving adjuvant CRT (n = 299) were 25.2% (95% CI,
20.3% to 31.2%) and 10.3% (95% CI, 6.6% to 16.0%), respectively, and for those
undergoing surgery alone (n = 374) were 28.7% (95% CI, 24.1% to 34.3%) and 15.9% (95%
CI, 11.7% to 21.6%), respectively. Disease-free survival with chemoradiation therapy versus
surgery, p = 0.552 by log rank analysis.
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Kaplan-Meier survival curves for disease-free survival for treatment groups stratified by
resection margin and lymph node (LN) status. (A) Patients with either R0 or R1 resection
margin showed no differences in disease-free survival with adjuvant chemoradiation therapy
(CRT) compared with those undergoing surgery alone (R0 CRT [n = 200] versus R0 surgery
[n = 298]), p = 0.429; R1 CRT [n = 99] versus R1 surgery [n = 76], p = 0.156. (B) Patients
with LN-negative disease who received adjuvant CRT had significantly worse disease-free
survival compared with patients undergoing surgery alone (LN− CRT [n = 106] versus LN−
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surgery [n = 164], p = 0.034). For LN-positive patients, a significant benefit was seen with
adjuvant CRT compared with patients undergoing surgery alone (LN+ CRT [n = 193] versus
LN+ surgery [n = 208], p < 0.001).
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(n = 299) p Value
Age at operation, y* 67 ± 11.7 63 ± 10.3 <0.001
Male gender, n (%) 211 (56) 160 (54) 0.586
Institution, n (%)
    1 12 (3) 20 (7)
    2 80 (21) 60 (20)
    3 103 (27) 75 (25)
    4 106 (28) 22 (7)
    5 13 (3) 13 (4)
    6 42 (11) 37 (12)
    7 22 (6) 72 (24)
Tumor size, cm* 3.03 ± 1.36 3.28 ± 1.45 0.048
Tumor grade, n (%)
    1 32 (9) 27 (9) 0.476
    2 223 (59) 163 (55)
    3 108 (29) 100 (34)
    4 13 (3) 7 (2)
Location of tumor, n (%)
    Head 352 (93) 269 (90) 0.135
    Body 6 (2) 12 (4)
    Tail 20 (5) 18 (6)
Vein resection, yes, n (%) 45 (12) 45 (15) 0.255
Margin, positive, n (%) 76 (20) 99 (33) <0.001
Lymph nodes, positive,
n (%) 210 (56) 193 (65) 0.027
Lymph nodes resected,
n (range) 8.5 (0–58) 10 (0–41) 0.280
Blood loss, mL* 797 ± 826 832 ± 834 0.405
Transfusions, yes, n (%) 105 (28) 88 (30) 0.668
Complications, yes, n (%) 132 (35) 101 (34) 0.807
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Table 3
Cox Proportional Hazards Model for Overall Survival and Radiation
Variable Hazard 95% CI p Value
CRT versus operation, LN
negative 0.810 0.556–1.181 0.270
CRT versus operation, LN
positive* 0.477 0.357–0.638 <0.0001
Positive lymph nodes, yes/no 1.765 1.313–2.372 0.0002
Age at operation, y 1.012 1.002–1.023 0.021
Gender, versus female 1.028 0.827–1.278 0.800
Tumor size, cm 1.103 1.015–1.199 0.021
Tumor grade 2 versus 1 1.912 1.217–3.002 0.005
Tumor grade 3 versus 1 2.720 1.691–4.376 <0.0001
Tumor location body versus
head 1.064 0.419–2.703 0.900
Tumor location tail versus
head 1.078 0.647–1.798 0.770
Blood loss per 100U change 1.018 1.004–1.031 0.010
Transfusion versus none 1.189 0.916–1.542 0.190
Vein resection versus none 0.924 0.663–1.288 0.640
Complications in 30 d 1.169 0.911–1.499 0.220
Lymph nodes resected 0.995 0.977–1.012 0.540
Margin, positive versus
negative 1.510 1.192–1.913 <0.001
*
A single model with an interaction term between LN status and treatment generated the estimates in this table, and provided estimates of the
treatment effect within LN groups. Although not shown in this table, this term had a hazard of 0.589, with a 95% CI of 0.378 to 0.916 and a p value
of 0.0190. CRT, chemoradiation therapy; LN, lymph node.
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Table 4
Cox Proportional Hazards Model for Disease-Free Survival and Radiation
Variable Hazard 95% CI p Value
CRT versus operation, LN
negative 1.170 0.832–1.645 0.370
CRT versus operation, LN
positive* 0.566 0.437–0.733 <0.0001
Positive lymph nodes, yes/no 1.971 1.491–2.605 <0.0001
Age at operation, y 1.011 1.001–1.020 0.028
Gender, versus female 0.992 0.815–1.208 0.940
Tumor size, cm 1.083 1.008–1.163 0.030
Tumor grade 2 versus 1 1.915 1.291–2.842 0.001
Tumor grade 3 versus 1 2.560 1.681–3.901 <0.0001
Tumor location body versus
head 1.534 0.807–2.918 0.190
Tumor location tail versus
head 1.104 0.715–1.705 0.650
Blood loss per 100U change 1.031 1.016–1.047 0.0001
Transfusion versus none 1.022 0.802–1.302 0.860
Vein resection versus none 1.083 0.806–1.456 0.600
Complications in 30 d 1.167 0.934–1.459 0.170
Lymph nodes resected 0.997 0.982–1.013 0.740
Margin, positive versus
negative 1.437 1.156–1.787 0.001
*
A single model with an interaction term between LN status and treatment generated the estimates in this table and provided estimates of the
treatment effect within LN groups. While not shown in the table above, this term had a hazard of 0.484, with a 95% CI of 0.324 to 0.724 and a p
value of 0.0004. CRT, chemoradiation therapy; LN, lymph node.
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